BLASUBCUTANEOUSSOLUTION
Approved
Nov 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
XULTOPHY 100/3.6 (insulin degludec and liraglutide) by Novo Nordisk is glucagon-like peptide-1 (glp-1) agonists [moa]. Approved for insulin analog [epc]. First approved in 2016.
Drug data last refreshed 13h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XULTOPHY 100/3.6 is a fixed-dose combination of insulin degludec (basal insulin) and liraglutide (GLP-1 agonist) administered via subcutaneous injection. It is indicated for type 2 diabetes and combines long-acting insulin with incretin-mimetic therapy to improve glycemic control. The dual mechanism provides both basal insulin replacement and GLP-1-mediated glucose-dependent insulin secretion and appetite suppression.
Peak
Product is at peak commercial maturity as of 2016 approval; team likely stable with focus on market penetration and key account management.
Mechanism of Action
Glucagon-like Peptide-1 (GLP-1) Agonists
Pharmacologic Class:
Insulin Analog
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese Subjects
Started Sep 2017
24 enrolled
DiabetesDiabetes Mellitus, Type 2
A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Japanese Subjects With Type 2 Diabetes Mellitus.
Started Nov 2015
819 enrolled
DiabetesDiabetes Mellitus, Type 2
Dual Action of Liraglutide and Insulin Degludec in Type 2 Diabetes: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide, Insulin Degludec and Liraglutide in Subjects With Type 2 Diabetes
Started May 2011
1,663 enrolled
DiabetesDiabetes Mellitus, Type 2
Worked on XULTOPHY 100/3.6 at Novo Nordisk? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.